Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35:20 2023-01-27 am EST
10622.00 GBX   -0.21%
01/26US FDA Cancels Emergency Use Nod For AstraZeneca's COVID-19 Drug
MT
01/26ADRs End Higher; AstraZeneca, Diageo Trade Actively
DJ
01/26AstraZeneca loses emergency use authorisation for Evusheld
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Signs Licensing Deal with C4X Discovery

11/28/2022 | 03:21am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.21% 10622 Delayed Quote.-5.31%
C4X DISCOVERY HOLDINGS PLC -0.29% 17.35 Delayed Quote.-3.61%
All news about ASTRAZENECA PLC
01/26US FDA Cancels Emergency Use Nod For AstraZeneca's COVID-19 Drug
MT
01/26ADRs End Higher; AstraZeneca, Diageo Trade Actively
DJ
01/26AstraZeneca loses emergency use authorisation for Evusheld
AN
01/26U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld
RE
01/26AstraZeneca's COVID-19 Therapy Evusheld Is No Longer Authorized for Emergency Use by US..
MT
01/26FDA Halts Authorization of AstraZeneca's Evusheld for Prophylactic Use
DJ
01/26Astrazeneca plc Announces Update on US Food and Drug Administration Emergency Use Autho..
CI
01/26Astrazeneca : Update on US Food and Drug Administration Emergency Use Authorisation of Evu..
PU
01/26U.S. FDA withdraws authorization for AstraZeneca's Evusheld
RE
01/26Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-lo..
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 454 M - -
Net income 2022 4 027 M - -
Net Debt 2022 24 214 M - -
P/E ratio 2022 51,0x
Yield 2022 2,24%
Capitalization 204 B 204 B -
EV / Sales 2022 5,13x
EV / Sales 2023 4,84x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 131,52 $
Average target price 153,20 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-5.31%203 823
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-4.87%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
MERCK & CO., INC.-5.02%267 180